Reflux-related Complications in Patients with Chronic Calculous Prostatitis and Benign Prostate Hyperplasia After Surgical Removal of Prostatic Hyperplasia and Stones
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
The objective: to analyze the effectiveness of prevention of reflux-related complications in patients with chronic calculous prostatitis and prostatic hyperplasia after surgical removal of prostatic hyperplasia and stones.
Materials and methods. The study included patients 56–70 years old with prostatic hyperplasia and stones. They were divided into two groups. The first group included 28 patients who underwent a retrospective study of reflux pyelonephritis and epididymitis after surgical removal of hyperplastic tissues and stones of the prostate gland without the use of pathogenetically justified prophylaxis. The second group included 26 patients who underwent a study of reflux pyelonephritis and epididymoorchitis after surgical removal of hyperplastic tissues and stones of the prostate gland with the use of pathogenetic justified drug therapy.
The patients underwent objective, laboratory, bacteriological and biochemical research, ultrasound examination of the prostate gland and bladder. Blood flow in the prostate gland was studied by Doppler.
Results. In 14.2 % of patients in the first group, who received traditional medical treatment in the postoperative period, acute reflux pyelonephritis developed, in 17.8 % – epididymitis. Patients of the second group were prescribed one of the alpha1-adrenoceptor blockers and suppositories with a non-steroidal drug in the postoperative period together with traditional medical therapy. In patients of the second group, acute reflux pyelonephritis was not determined after surgical treatment, and epididymitis developed in 1 (3.3 %) of 26 persons.
Conclusions. It has been determined that the prescription of alpha1-adrenoceptor blocker is an effective method of preventing of reflux-related pyelonephritis and epididymitis development in the patients in the early postoperative period after surgical removal of hyperplastic tissues and stones of the prostate gland in order to eliminate spastic obstruction, as well as prescription of non-steroidal drug to reduce the inflammatory process and edema in the prostate and bladder neck.
##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Persson BE, Ronguist G. Evidense for a mechanistic association between nonbacterial prostatitis and levels of urate and creatinine in expressed prostatic secretion. J Urol (Baltimore). 1996;155(3):958–60.
Uhal OM, inventor. Odesa State Medical University, patent holder. A method of modeling chronic prostatitis. Patent No. 47121. 2010 Jan 11. Ukraine.
Ukhal OM, Ukhal MY, Kostev FI, Ulyanov VO. Peculiarities of morphogenesis of experimental reflux-induced chronic prostatitis. Men’s Health. 2010;(4):137–40.
Nickel JC, Downey J, Johnston B, Clark J, Canadian Prostatitis Research Group. Predictors of patient response to antibiotic therapy for the chronic рrostatitis/chronic pelvic pain syndrome: a prospective multicenter clinical trial. J Urol. 2001;165(5):1539–44.
Naber KG. Chronic (Bacterial) Prostatitis. Complicated Urinary Tract Infections: Lectures in Hospital Infections. London; 2003, p. 13–31.
Rudick CN, Berry RE, Johnson JR, Johnston B, Klumpp DJ, Schaeffer AJ, et al. Uropathogenic Escherichia coli induces chronic pelvic pain. Infect Immun. 2011;79(2):628–35. doi: 10.1128/IAI.00910-10.
Krieger JN, Riley DE. Bacteria in the chronic prostatitis-chronic pelvic pain syndrome: molecular approaches to critical research questions. J Urol. 2002;167(6):2574–83.
Nadler RB, Collins MM, Propert KJ, Mikolajczyk SD, Knauss JS, Landis JR, et al. Prostate-specific antigen test in diagnostic evaluation of chronic prostatitis/chronic pelvic pain syndrome. Urol. 2006;67(2):337–42. doi: 10.1016/j.urology.2005.08.031.
Garcia-Castillo M, Morosini МM, Galvez М. Differences in biofilm development and antibiotic susceptibility among clinical Ureaplasma urealyticum and Ureaplasma parvum isolates. J Antimicrob Chemother. 2008;62(5):1027–30. doi: 10.1093/jac/dkn337.
Cai T. Epidemiological features and resistance pattern in uropathogens isolated from chronic bacterial prostatitis. J Microbiol. 2011;49(3):448–54. doi: 10.1007/s12275-011-0391-z.
Propert KJ, Mc. Naughton-Collins M, Leiby BE. A prospective study of symptoms and quality of life in men with chronic prostatitis/chronic pelvic pain syndrome: the National Institutes of Health chronic prostatitis cohort study. J Urol. 2006;175(2):619–23. doi: 10.1016/S0022-5347(05)00233-8.
Schaeffer AJ, Anderson RU, Krieger JN. The assessment and management of male pelvic pain syndrome, including prostatitis. Management 6th International Consultation on New Developments in Prostate Cancer and Prostate Disease. Paris; 2006, p. 341–85.
Nickel JC. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline from the REDUCE trial. Eur Urol. 2008;54(6):1379–84. doi: 10.1016/j.eururo.2007.11.026.
Wagenlehner FM, Naber KG, Bschleipfer T, Brahler E, Weidner W. Prostatitis and Male Pelvic Pain Syndrome Diagnosis and Treatment. Dtsch Arztebl Int. 2009;106(11):175–83. doi: 10.3238/arztebl.2009.0175.
Uhal OM. Functional disorders of urodynamics of the lower urinary tract and their role in the development and progression of chronic prostatitis and cystitis (experimental and clinical studies) [abstract]. Kyiv: State Institute of Urology of the National Academy of Sciences of Ukraine; 2011. 37 p.
Cai T, Mazzoli S, Meacci F, Boddi V, Mondaini N, Malossini G, et al. Epidemiological features and resistance pattern in uropathogens isolated from chronic bacterial prostatitis. J Microbiol. 2011;49(3):448–54. doi: 10.1007/s12275-011-0391-z
Кulchavenya EV, Neymark AI. Prostatitis. Diagnostics and treatment. Moscow: GEOTAR-media; 2010. 256 p.
Zhao WP, Li YT, Chen J, Zhang Z-G, Jiang H, Xia D, et al. Prostatic calculi influence the antimicrobial efficacy in men with chronic bacterial prostatitis. Asian J Androl. 2012;15(4):715–20. doi: 10.1038/aja.2012.40.
Simeone C, Pezzotti G, Zani D. Is symptomatic benign prostatic hypertrophy due to an autonomic disease? In: Abstracts from the 14th Congress of the EAU. 1999 April 10-13; Stockholm. Stockholm: European Association of Urology; 1999; 196 p. doi: 10.1159/isbn.978-3-318-06207-6.
Kefi A, Koseoglu H, Celebi I. Relation of high PSA accompanying acute urinary retention with prostatitis. In: Abstracts from the XIХth Congress of the EAU. Vienna: European Association of Urology; 2004. p. 144.
Nickel JC. Inflammation and benign prostatic hyperplasia. Urol Clin North Am. 2008;35(1):109–15. doi: 10.1002/pros.21027.
Nickel JC, Roehrborn CG, O’Leary MP. The relationship between prostate inflammation and ower urinary tract symptoms: examination of baseline from the REDUCE. Eur Urol. 2008;54(6):1385–8. doi: 10.1016/j.eururo.2007.11.026.
Horpinchenko II, Gurzhenko Y. Use of the α-adrenoblocker Setegys in the treatment of patients with chronic prostatitis. Men’s Health. 2003;(3):60–3.
Pirogov VA, Bondarenko Y. The use of Omnic in the treatment of patients with urinary dysfunction of various origins. Man’s Health. 2005;(3):124–7.
Qin GD, Xiao MZ, Zhou YD, Yang J, He H-X, He Y, Zeng Y. Tamsulosin alters levofloxacin pharmacokinetics in prostates derived from rats with acute bacterial prostatitis. Asian J Androl. 2013;15(2):254–60. doi: 10.1038/aja.2012.134.
Magri V, Marras E, Restelli A, Wagenlehner FME, Perletti G. Multimodal therapy for category III chronic prostatitis/chronic pelvic pain syndrome in UPINTS phenotyped patients. Exp Ther Med. 2015;9(3):658–66. doi: 10.3892/etm.2014.2152.
Elmalic E, Ibrahim A, Cahli A, Saad MS, Bahar YM. Risk factors in prostatectomy bleeding preoperative urinary infection is the only reversible factor. Eur Urol. 2000;37(2):199–204. doi: 10.1159/000020118.
Vozianov OF, Pasechnik SP, Gritsai VS. Influence of the chronic ignition process of the anterior sinus and sciatica on the symptoms of the lower sciatica paths in patients with benign hyperplasia of the anterior lesion. Urol. 2006;(4):12–4.
Uhal OM, inventor. Odesa State Medical University, patent holder. The method of non-invasive diagnosis of urethroprostatic reflux of urine in patients with chronic prostatitis according to O.M. Ukhal. Patent No. 44052. 2009 Sep 10. Ukraine.
